

Marie Robin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1053606/publications.pdf>

Version: 2024-02-01

157
papers

5,812
citations

57758

44
h-index

91884

69
g-index

162
all docs

162
docs citations

162
times ranked

5488
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	1.4	278
2	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. <i>Leukemia</i> , 2015, 29, 2126-2133.	7.2	242
3	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
4	Long-term outcome after bone marrow transplantation for severe aplastic anemia. <i>Blood</i> , 2004, 103, 2490-2497.	1.4	192
5	Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie-Cellulaire and the Groupe-Francophone des My�lodysplasies. <i>Journal of Clinical Oncology</i> , 2012, 30, 4533-4540.	1.6	188
6	Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). <i>Journal of Clinical Oncology</i> , 2017, 35, 2157-2164.	1.6	183
7	A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality. <i>Blood</i> , 2014, 124, 188-188.	1.4	147
8	Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. <i>Haematologica</i> , 2016, 101, 879-883.	3.5	126
9	Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. <i>Blood</i> , 2015, 125, 775-783.	1.4	122
10	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. <i>Blood</i> , 2019, 133, 2233-2242.	1.4	121
11	Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. <i>Haematologica</i> , 2007, 92, 1254-1257.	3.5	118
12	The eukaryotic gut virome in hematopoietic stem cell transplantation: new clues in enteric graft-versus-host disease. <i>Nature Medicine</i> , 2017, 23, 1080-1085.	30.7	109
13	Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. <i>Leukemia</i> , 2013, 27, 604-609.	7.2	105
14	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci�t� Fran�saise de Greffe de Moelle et de Th�rapie Cellulaire (SFGM�TC). <i>British Journal of Haematology</i> , 2011, 152, 331-339.	2.5	104
15	Budesonide/Formoterol for Bronchiolitis Obliterans after Hematopoietic Stem Cell Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1242-1249.	5.6	93
16	Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation Anticytokine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 406-413.	2.0	91
17	Metabolomics analysis of human acute graft-versus-host disease reveals changes in host and microbiota-derived metabolites. <i>Nature Communications</i> , 2019, 10, 5695.	12.8	91
18	Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. <i>Haematologica</i> , 2020, 105, 91-101.	3.5	86

#	ARTICLE	IF	CITATIONS
19	Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with $\geq 10\%$ BM blasts: a report from EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 761-770.	2.4	82
20	Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 237-245.	3.5	82
21	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	2.5	80
22	Fecal calprotectin and alpha-1 antitrypsin predict severity and response to corticosteroids in gastrointestinal graft-versus-host disease. <i>Blood</i> , 2012, 119, 5909-5917.	1.4	79
23	Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. <i>European Respiratory Journal</i> , 2018, 51, 1702617.	6.7	71
24	Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1206-1211.	2.0	70
25	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
26	Bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. <i>Bone Marrow Transplantation</i> , 2013, 48, 819-824.	2.4	67
27	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>European Journal of Haematology</i> , 2013, 90, 355-364.	2.2	66
28	Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. <i>Blood Advances</i> , 2019, 3, 2424-2435.	5.2	66
29	HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. <i>Leukemia</i> , 2015, 29, 1496-1501.	7.2	65
30	The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 958-964.	2.0	61
31	Patterns of Cytomegalovirus Reactivation Are Associated with Distinct Evolutionary Profiles of Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2008, 198, 818-826.	4.0	57
32	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. <i>Haematologica</i> , 2019, 104, 659-668.	3.5	56
33	Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity. <i>Blood Advances</i> , 2020, 4, 1824-1832.	5.2	54
34	Risk Factors for Late Infections after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1304-1312.	2.0	53
35	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
36	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 489-495.	2.0	53

#	ARTICLE	IF	CITATIONS
37	Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 810-818.	2.0	52
38	Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. <i>Haematologica</i> , 2011, 96, 291-297.	3.5	51
39	Impact of the revised international Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 400-408.	3.5	50
40	Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc. <i>Blood</i> , 2013, 122, 306-306.	1.4	50
41	Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 44-52.	2.0	49
42	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Haematologica</i> , 2019, 104, 1782-1788.	3.5	48
43	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
44	Unrelated cord blood transplantation in adults with myelodysplasia or secondary acute myeloblastic leukemia: a survey on behalf of Eurocord and CLWP of EBMT. <i>Leukemia</i> , 2011, 25, 75-81.	7.2	47
45	Increased Infection Rate After Preemptive Rituximab Treatment for Epstein-Barr Virus Reactivation After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Transplantation</i> , 2012, 94, 879-883.	1.0	47
46	Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. <i>Leukemia</i> , 2013, 27, 879-888.	7.2	47
47	The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 141-144.	2.0	46
48	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1615-1620.	2.0	46
49	Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Soci� Fran�aise de Greffe de Moelle et de Th�rapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1349-1355.	2.0	44
50	Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2007, 137, 248-251.	2.5	41
51	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2021, 96, 69-79.	4.1	40
52	Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. <i>Leukemia</i> , 2021, 35, 3551-3560.	7.2	40
53	Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Fran�aise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2014, 49, 756-760.	2.4	38
54	Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2017, 52, 209-215.	2.4	37

#	ARTICLE	IF	CITATIONS
55	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021, 35, 2445-2459.	7.2	36
56	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2021, 35, 215-224.	7.2	34
57	Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cellular Therapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 240-247.	2.0	31
58	Quantification of the Mutant CALR Allelic Burden by Digital PCR. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 68-74.	2.8	30
59	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <sc>EBMT</sc> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	4.1	30
60	Clinical Severity Scores in Gastrointestinal Graft-Versus-Host Disease. <i>Transplantation</i> , 2014, 97, 965-971.	1.0	29
61	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	5.2	28
62	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <sc>EBMT</sc>. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	2.5	28
63	HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 114-120.	2.0	27
64	Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 3353-3359.	1.4	26
65	Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 451-457.	2.0	25
66	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2160-2172.	2.4	25
67	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. <i>PLoS ONE</i> , 2013, 8, e74368.	2.5	25
68	Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 646-654.	2.0	24
69	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 686-695.	7.2	24
70	Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation. <i>Haematologica</i> , 2019, 104, 929-936.	3.5	23
71	Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e204-e208.	2.0	23
72	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. <i>Blood Advances</i> , 2021, 5, 1760-1769.	5.2	22

#	ARTICLE	IF	CITATIONS
73	Is there still a place for myeloablative regimen to transplant young adults with sickle cell disease?. <i>Blood</i> , 2011, 118, 4491-4492.	1.4	20
74	Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study. <i>Haematologica</i> , 2022, 107, 1054-1063.	3.5	20
75	Reduced intensity hematopoietic stem cell transplantation for Accelerated-phase myelofibrosis. <i>Blood Advances</i> , 2022, 6, 1222-1231.	5.2	20
76	correspondence: Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis. <i>British Journal of Haematology</i> , 2010, 150, 721-724.	2.5	19
77	Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2011, 46, 557-561.	2.4	19
78	Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2014, 99, 1492-1498.	3.5	19
79	Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Transplantation</i> , 2015, 99, 1672-1680.	1.0	19
80	Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2017, 52, 1107-1112.	2.4	19
81	Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , 2017, 52, 1519-1525.	2.4	19
82	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2523-2531.	2.0	19
83	Fecal calprotectin and α 1-antitrypsin dynamics in gastrointestinal GvHD. <i>Bone Marrow Transplantation</i> , 2015, 50, 1105-1109.	2.4	18
84	High Number of Memory T Cells Is Associated with Higher Risk of Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 569-574.	2.0	18
85	Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. <i>Clinical Microbiology and Infection</i> , 2016, 22, 289.e1-289.e7.	6.0	18
86	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups. <i>Bone Marrow Transplantation</i> , 2021, 56, 1888-1899.	2.4	18
87	Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 725-732.	2.5	17
88	Sinusoidal obstruction syndrome. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 480-485.	1.5	17
89	Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. <i>American Journal of Hematology</i> , 2021, 96, 80-88.	4.1	17
90	Low-dose Thoracoabdominal Irradiation for the Treatment of Refractory Chronic Graft-versus-Host Disease. <i>Transplantation</i> , 2005, 80, 634-642.	1.0	16

#	ARTICLE	IF	CITATIONS
91	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2016, 172, 628-630.	2.5	16
92	A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 2404-2414.	1.3	15
93	Elastography improves accuracy of early hepato-biliary complications diagnosis after allogeneic stem cell transplantation. <i>Haematologica</i> , 2021, 106, 2374-2383.	3.5	14
94	Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. <i>Blood</i> , 2022, 140, 1408-1418.	1.4	13
95	Dynamics of cytomegalovirus populations harbouring mutations in genes UL54 and UL97 in a haematopoietic stem cell transplant recipient. <i>Journal of Clinical Virology</i> , 2013, 58, 733-736.	3.1	12
96	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. <i>European Journal of Haematology</i> , 2019, 103, 552-557.	2.2	12
97	Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis. <i>Haematologica</i> , 2019, 104, 1230-1236.	3.5	12
98	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. <i>British Journal of Haematology</i> , 2018, 183, 766-774.	2.5	11
99	Incidence of Acute Graft-Versus-Host Disease and Survival after Allogeneic Hematopoietic Cell Transplantation over Time: A Study from the Transplant Complications and Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 2120-2120.	1.4	11
100	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	2.4	11
101	Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 507-513.	2.0	10
102	Human-Derived α 1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1620-1626.	2.0	10
103	APRIL levels are associated with disease activity in human chronic graft-versus-host disease. <i>Haematologica</i> , 2016, 101, e312-e315.	3.5	9
104	Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. <i>Bone Marrow Transplantation</i> , 2018, 53, 105-107.	2.4	9
105	Epstein-Barr Virus-Associated Post-Transplantation Lymphoproliferative Disease in Patients Who Received Anti-CD20 after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2490-2500.	2.0	9
106	A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. <i>Bone Marrow Transplantation</i> , 2020, 55, 86-92.	2.4	9
107	Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?. <i>Leukemia</i> , 2020, 34, 2552-2560.	7.2	9
108	Should Transplantation Still Be Considered for Ph1-Negative Myeloproliferative Neoplasms in Transformation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1160-1170.	2.0	9

#	ARTICLE	IF	CITATIONS
109	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 38-49.	2.4	9
110	Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. <i>Leukemia</i> , 2021, 35, 225-228.	7.2	9
111	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	2.5	9
112	Impact of donor-derived CD34-infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 261-270.	2.4	9
113	Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 250-256.	2.0	8
114	Hypomethylating Agents as Bridging Therapy before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myelomonocytic Leukemia?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1-2.	2.0	8
115	Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 768-774.	2.4	8
116	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1448-1450.	2.0	7
117	GLCC11 and Glucocorticoid Receptor Genetic Diversity and Response to Glucocorticoid-Based Treatment of Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1246-1250.	2.0	7
118	Clinical profile, biological markers, and comorbidity index as predictors of transplant-related mortality after allo-HSCT. <i>Blood Advances</i> , 2017, 1, 1409-1413.	5.2	7
119	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	2.4	7
120	Comprehensive Clinical-Molecular Transplant Risk Model for Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 689-689.	1.4	6
121	Double Cord Blood Transplantation for Patients with High Risk Hematological Diseases: Delayed Immune Recovery and High Incidence of Infections.. <i>Blood</i> , 2006, 108, 2923-2923.	1.4	6
122	Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC). <i>Bone Marrow Transplantation</i> , 2022, 57, 125-127.	2.4	6
123	RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea. <i>Blood Advances</i> , 2022, 6, 2805-2811.	5.2	6
124	Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. <i>European Journal of Haematology</i> , 2018, 101, 466-474.	2.2	5
125	Metabolomics Profiling after Allogeneic Hematopoietic Stem Cell Transplantation Unravels a Specific Signature in Human Acute GVHD. <i>Blood</i> , 2018, 132, 69-69.	1.4	5
126	Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial). <i>Blood</i> , 2014, 124, 320-320.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. <i>Haematologica</i> , 2016, 101, e209-e212.	3.5	4
128	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. <i>Current Research in Translational Medicine</i> , 2019, 67, 8-15.	1.8	4
129	Contemporary treatment approaches to CMML – Is allogeneic HCT the only cure?. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101138.	1.7	4
130	Outcome of allogeneic haematopoietic stem cell transplantation in myeloproliferative neoplasm, unclassifiable: a retrospective study by the Chronic Malignancies Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 190, 437-441.	2.5	4
131	On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 34-43.	0.4	4
132	Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 23-30.	2.4	4
133	Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1072-1078.	2.4	4
134	Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. <i>Blood Advances</i> , 2022, 6, 4763-4772.	5.2	4
135	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2366-2374.	2.0	3
136	Complete remission of sclerodermatous cutaneous graft-versus-host disease after low-dose interleukin-2 treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e791-e793.	2.4	3
137	Allogeneic Stem Cell Transplantation for MDS. <i>Hemato</i> , 2021, 2, 545-555.	0.6	3
138	Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Group and the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2019, 134, 4581-4581.	1.4	3
139	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
140	Success of haploidentical hematopoietic stem cells transplantation in the treatment of graft failure. <i>Annals of Hematology</i> , 2016, 95, 353-354.	1.8	2
141	Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Soci�t� Francophone de Greffe de Moelle et de Therapie Cellulaire. <i>Bone Marrow Transplantation</i> , 2021, 56, 2849-2856.	2.4	2
142	Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial). <i>Blood</i> , 2018, 132, 1019-1019.	1.4	2
143	Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. <i>Bone Marrow Transplantation</i> , 2022, 57, 896-902.	2.4	2
144	Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report. <i>Annals of Hematology</i> , 2020, 99, 897-898.	1.8	1

#	ARTICLE	IF	CITATIONS
145	Outcomes Following Second Allogeneic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT. Blood, 2019, 134, 698-698.	1.4	1
146	Allogeneic Stem Cell Transplantation for MDS. Hematologic Malignancies, 2018, , 141-157.	0.2	0
147	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.6	0
148	Pulmonary Alveolar Proteinosis After Allogeneic Stem Cell Transplantation: A French National Survey 2000-2018. , 2020, , .		0
149	Alternative Donor Stem Cell Transplantation after Reduced Intensity Conditioning Regimen for Patients with Bone Marrow Failure.. Blood, 2005, 106, 2894-2894.	1.4	0
150	Mycophenolate Mofetil (MMF) with or without Tracolimus (FK506) as a Second Line Treatment for Steroid-Resistant Acute Graft-Versus-Host Disease. The Experience of Saint Louis Hospital.. Blood, 2006, 108, 2892-2892.	1.4	0
151	Initial Liver Involvement in Acute Graft-Versus-Host Disease (GVHD) Predicts a Severe Acute Gvhd and Poor Long-Term Survival. Blood, 2008, 112, 1164-1164.	1.4	0
152	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as a Curative Therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period Oligocentric French Experience.. Blood, 2008, 112, 1756-1756.	1.4	0
153	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2014, 124, 1216-1216.	1.4	0
154	Prognostic Value of Cpss Cytogenetic Risk Classification in Patients with CMML after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study of the Chronic Malignancies Working Party of the EBMT. Blood, 2018, 132, 2182-2182.	1.4	0
155	Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party. Blood, 2018, 132, 4390-4390.	1.4	0
156	Sexual Life, Fertility and Ovarian Function in Women after Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2019, 134, 3301-3301.	1.4	0
157	Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population. Blood, 2021, 138, 4133-4133.	1.4	0